Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration when treatment initiated in Emergency Rooms. (SHORTER-Study). International journal of stroke : official journal of the International Stroke Society Alhazzani, A., AlAjlan, F., Alkhathaami, A., Al-Senani, F. M., Muayqil, T., Alghamdi, S., AlKawi, A., AlZahrani, S., Bakheet, M., Aljohani, M., Taher, N., Almutairi, A., AlQarni, M., Alsalman, S., Alqahtani, S., Almansour, N., Abukhamsin, L., Mouminah, A., AlModarra, N. B., Mohamed, G., Almodhy, M., Albogumi, E. A., AlZawahmah, M., AlReshaid, A., Akhtar, N., Hussain, M. S., Albers, G. W., Shuaib, A. 2024: 17474930241237120

Abstract

Following TIA and minor stroke, the risk of recurrent stroke can be significantly reduced with short duration dual antiplatelet therapy (DAPT). We wish to investigate if 10 days of DAPT is as effective as 21 days treatment.This is an open-label, randomized, parallel-group study comparing whether 10 days of DAPT treatment (ASA+Clopidogrel) is non-inferior to 21-day of DAPT. in patients with minor ischemic stroke (AIS) or high-risk transient ischemic attack (TIA). In both groups DAPT is started within 24 hours of symptom onset.This study is being conducted in approximately 15 study sites in the Kingdom of Saudi Arabia. The planned sample size if 1932.Noninferiority of 10 days compared to 21 days of DAPT in the prevention of the composite endpoint of stroke and death at 90 days in AIS/TIA patients. The primary safety outcome is major intracranial and systemic hemorrhage.Enrolment started in the second quarter of 2023, and the completion of the study is expected in the fourth quarter of 2025.The trial is expected to show that 10 days of DAPT is non-inferior for the prevention of early recurrence of vascular events in patients with high-risk TIAs and minor strokes.

View details for DOI 10.1177/17474930241237120

View details for PubMedID 38395748